Delta-Omicron recombinant escapes therapeutic antibody neutralization.
iScience
; 26(2): 106075, 2023 Feb 17.
Article
in English
| MEDLINE | ID: covidwho-2240400
ABSTRACT
The emergence of recombinant viruses is a threat to public health, as recombination may integrate variant-specific features that together result in escape from treatment or immunity. The selective advantages of recombinant SARS-CoV-2 isolates over their parental lineages remain unknown. We identified a Delta-Omicron (AY.45-BA.1) recombinant in an immunosuppressed transplant recipient treated with monoclonal antibody Sotrovimab. The single recombination breakpoint is located in the spike N-terminal domain adjacent to the Sotrovimab binding site. While Delta and BA.1 are sensitive to Sotrovimab neutralization, the Delta-Omicron recombinant is highly resistant. To our knowledge, this is the first described instance of recombination between circulating SARS-CoV-2 variants as a functional mechanism of resistance to treatment and immune escape.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Variants
Language:
English
Journal:
IScience
Year:
2023
Document Type:
Article
Affiliation country:
J.isci.2023.106075
Similar
MEDLINE
...
LILACS
LIS